Loading data for ABEO — first visit, this takes a few seconds.
Abeona Therapeutics Inc. (ABEO)
NasdaqCM: ABEO
· 即時價格 · USD
5.42
-0.06 (-1.09%)
收盤價： Sep 11, 2026, 3:59 PM
5.47
+0.98%
盤後: 7:30 PM
股價、關鍵數字和最新消息，都在這一頁。
Abeona Therapeutics Inc.（ABEO）股價、分析與資料
-1.19% (1D)
| 買價 | 3.96 |
| 市值 | 310M |
| 營收 (ttm) | 25.5M |
| 淨利（ttm） | -62.9M |
| 1.32 | |
| -1.21 | |
| n/a | |
| -29.01 | |
| P/B (ttm) | 2.42 |
| P/S (ttm) | 12.13 |
| 財報日期 | Nov 11, 2026 |
| 賣價 | 6.93 |
| 成交量 | 1,548,004 |
| 20 日平均成交量 | 1,438,158 |
| 開盤價 | 5.55 |
| 前收盤價 | 5.48 |
| 當日區間 | 5.40 - 5.66 |
| 52 週範圍 | 4.00 - 7.65 |
| 分析師 | n/a |
| 目標價 | n/a |
| 股利 | n/a |
| 除息日 | n/a |
關於 ABEO
Abeona Therapeutics Inc., a commercial-stage biopharmaceutical company, develops gene and cell therapies for life-threatening diseases in the United States. It develops ZEVASKYN, an autologous, cell-based gene therapy for the treatment of patients with recessive dystrophic epidermolysis bullosa. The company also develops ABO-503 to treat X-linked retinoschisis; ABO-504 for the treatment of stargardt disease; and ABO-505 to treat autosomal dominan...
完整的公司簡介財報驚奇
Abeona Therapeutics 已於 Aug 13, 2026 公布季度財報：
- 營收為 $8.72M 低於預期 $0, 年增 Infinity% 成長.
- 每股盈餘為 -0.35 低於預期 -0.11, 年增 25.53% 成長.
第 1 頁，共 2 頁